An Erlotinib gold(I) conjugate for combating triple-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An Erlotinib gold(I) conjugate for combating triple-negative breast cancer

Published:2020-02 Issue: Volume:203 Page:110910
ISSN:0162-0134
Container-title:Journal of Inorganic Biochemistry
language:en
Short-container-title:Journal of Inorganic Biochemistry

Author:

Ortega Enrique,Zamora Ana,Basu Uttara,Lippmann Petra,Rodríguez Venancio,Janiak Christoph,Ott Ingo,Ruiz José

Funder

Ministerio de Ciencia, Innovación y Universidades

FEDER

Fundación Séneca-CARM

DFG

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Inorganic Chemistry,Biochemistry

Reference33 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. BRCA1-associated triple-negative breast Cancer and potential treatment for ruthenium-based compounds;Hongthong;Curr. Cancer Drug Targets,2016

3. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities;Yarden;Eur. J. Cancer,2001

4. Erlotinib hydrochloride;Dowell;Nat. Rev. Drug Discov.,2005

5. Cisplatin in cancer therapy: molecular mechanisms of action;Dasari;Eur. J. Pharmacol.,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy;European Journal of Pharmacology;2024-10

2. Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines;Bioorganic & Medicinal Chemistry Letters;2024-09

3. Insights Into Benzothiazolyl‐Coupled Azetidinone Moieties Toward EGFR Binding and Stability Analysis—Evidence From Molecular Docking and Dynamics Simulation;Peptide Science;2024-08-28

4. Organometallic–Erlotinib Conjugates Active against Lung Cancer Cells and as Emerging Virus Entry Inhibitors;Organometallics;2024-07-22

5. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3